Minor Histocompatibility Antigens

Known as: Minor Histocompatibility Peptides, Minor Histocompatibility Antigens [Chemical/Ingredient], minor histocompatibility antigen 
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1973-2017
0204019732017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
The adoptive transfer of donor T cells that recognize recipient minor histocompatibility antigens (mHAgs) is a potential strategy… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Minor histocompatibility antigens (mHAs) are known targets of donor T cells after allogeneic hematopoietic stem cell… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Donor lymphocyte infusion (DLI) into patients with a relapse of their leukemia or multiple myeloma after allogeneic stem cell… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Minor histocompatibility antigens (mHags) are immunogenic peptides from polymorphic cellular proteins that induce strong T-cell… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Human minor histocompatibility antigens (mHags) play an important role in the induction of cytotoxic T lymphocyte (CTL… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Graft-versus-host disease (GvHD) is a chief complication of allogeneic bone marrow transplantation. In HLA-identical bone marrow… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Effective immunotherapy for human leukemia based on infusions of T lymphocytes requires the identification of effector T cells… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Allogeneic bone marrow transplantation (BMT) is a common treatment of hematologic malignancies. Recurrence of the underlying… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1998
Highly Cited
1998
The minor histocompatibility antigen (mHag) HA-1 is the only known mHag for which mismatching is correlated with the development… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND Graft-versus-host disease (GVHD) can be a major complication of allogeneic bone marrow transplantation even when the… (More)
Is this relevant?